Author Affiliations: Centro de Cirugía Oftalmológica, Universidad Central de Venezuela, Caracas, Venezuela (Drs Cortez, Ramirez, and Collet); Departments of Ophthalmology, Duke University, Durham, North Carolina (Dr Thakuria); and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (Dr Giuliari).
To determine the effects of intraocular pressure (IOP) and needle diameter on the amount of reflux after intravitreous bevacizumab injection.
Prospective randomized interventional study. Twelve New Zealand white rabbits weighing approximately 2.5 to 3.5 kg each were randomized 1:1 to group 1 or group 2. Bevacizumab stained with trypan blue was used for intravitreous injection. To lower the IOP, eyes in group 2 underwent anterior chamber paracentesis before intravitreous injection. Two eyes in each group were injected using 27-, 30-, or 32-gauge needles. If a subconjunctival bleb formed after intravitreous injection, its diameter was measured using a caliper.
The median IOP in group 1 was 17.5 mm Hg. Eyes injected using 27-gauge and 30-gauge needles showed stained subconjunctival blebs with median sizes of 3 mm and 1.7 mm, respectively; eyes injected using 32-gauge needles showed no subconjunctival bleb formation. The median IOP in group 2 was 10.3 mm Hg. Eyes injected using 27-gauge needles showed stained subconjunctival blebs with a median size of 0.7 mm, and eyes injected using 30-gauge and 32-gauge needles showed no subconjunctival bleb formation.
Decreasing the IOP before intravitreous injection and using a smaller-gauge needle reduce the risk of drug reflux after intravitreous bevacizumab injection.
Intravitreous injection is an increasingly common route of drug delivery to treat ocular diseases. Techniques that maximize bioavailability are examined in this study.
Vascular endothelial growth factor (VEGF) acts in different physiologic processes, such as bone growth, tissue maintenance, wound healing, vasodilatation, and survival of various neuronal cell types, including retinal neurons.1- 5 It has an active role in trophic maintenance of capillaries in several organs. In the eye, development of the choriocapillaris is dependent on continuous trophic support via VEGF secreted by the retinal pigment epithelium.6,7 The production of VEGF is increased when these cell types are subjected to hypoxia.8 In recent years, a strong association has been found between VEGF and development of ocular neovascular diseases.9- 11
Bevacizumab is a potent monoclonal antibody that blocks all VEGF isoforms. Bevacizumab was the first anti-VEGF therapy approved by the US Food and Drug Administration for the treatment of breast, lung, and colorectal cancer.12 After the success of preliminary investigations with ranibizumab (an agent similar to bevacizumab) in the treatment of age-related macular degeneration, researchers and clinicians were motivated to systemically and intravitreously use bevacizumab off label to treat age-related macular degeneration and other forms of choroidal neovascular membranes.13- 15
Because of the significant adverse effects associated with the use of systemic anti-VEGF medications, a trend to administer bevacizumab by intravitreous injection has been seen among vitreoretinal surgeons.16,17 Although some authors advocate the ocular safety of bevacizumab,18- 20 it may enter the systemic circulation after the intravitreous route.17,21,22 Nevertheless, intravitreous injections of this agent provide an effective route for retinal neovascular disease therapy. A drawback of this technique is the risk of associated complications such as endophthalmitis, retinal detachment, and cataract formation.23 Recently, attention has been paid to other complications such as temporary intraocular pressure (IOP) increase and reflux of medication, with subconjunctival bleb formation after intravitreous injection.24- 26 Several ophthalmologists have modified the intravitreous injection technique in an effort to decrease the incidence of this reflux; however, most researchers have not considered the role of IOP.27,28
The objectives of this study were to determine the effects of IOP and needle diameter on the amount of reflux after intravitreous bevacizumab injection. We also aimed to determine if bevacizumab is present in the subconjunctival bleb.
This was a prospective randomized interventional study with direct comparison of the reflux after intravitreous bevacizumab injection and the effects of IOP and needle diameter on the amount of reflux, measured by subconjunctival bleb formation. The ethical committee of the Centro de Cirugía Oftalmológica and Universidad Central de Venezuela, Caracas, approved the study. All experiments were performed in accord with the research association for the use of animals at the Universidad Central de Venezuela.
Twelve New Zealand white rabbits weighing approximately 2.5 to 3.5 kg each were obtained from the Animal Research Department of the Universidad Central de Venezuela. Rabbits were chosen for this study because of their usefulness in the evaluation of new drugs and surgical procedures for glaucoma.29,30 They were randomized 1:1 to group 1 or group 2. Eyes in group 1 were considered the control group, as no attempt was made to lower the IOP. In group 2, anterior chamber paracentesis was performed to lower the IOP.31,32 Two eyes in each group were then randomized 1:1:1 to receive intravitreous bevacizumab injections using 27-, 30-, or 32-gauge needles.
Rabbits in both groups were anesthetized by a certified anesthesiologist using intramuscular ketamine hydrochloride injection.33,34 Topical anesthesia with proparacaine hydrochloride, 0.5%, was administered to each study eye 1 to 5 minutes before intravitreous injection. The intravitreous injection solution consisted of a mixture of 0.8 mL of bevacizumab and 0.2 mL of trypan blue. Trypan blue was used to stain the bevacizumab and to determine its presence if a subconjunctival bleb formed. The intravitreous injection was prepared in the usual manner. The ocular surface and cul-de-sac were rinsed generously with a povidone-iodine solution, 5%, while the eyelids were scrubbed with a cotton-tipped applicator soaked in povidone-iodine solution, 10%. After placing a sterile eyelid speculum, povidone-iodine solution, 5%, was applied directly over the injection site. Using a 30-gauge needle, eyes in group B underwent anterior chamber paracentesis in a controlled manner under magnification before intravitreous injection.35 The volume extracted by anterior chamber paracentesis varied from approximately 100 to 200 μL. Intraocular pressure was then assessed (Tono-Pen XL; Medtronic Solan, Jacksonville, Florida) in eyes of both groups. All intravitreous injections were performed by one of us (R.T.C.) with retina training and experience using an oblique intravitreous injection technique delivered 1.5 to 2 mm posterior to the superotemporal limbus. Using a 27-, 30-, or 32-gauge needle, 0.025 mL of the previously described bevacizumab–trypan blue mixture was injected. As soon as the needle was withdrawn, the external area was observed for the presence of any subconjunctival bleb that stained blue. If present, the subconjunctival bleb was measured using a straight Castroviejo caliper (K3-9000; Katena Products, Inc, Denville, New Jersey).
The primary end point was to determine if the IOP had an effect on the amount of reflux after intravitreous bevacizumab. Secondary end points were to determine if the needle diameter had a role in subconjunctival bleb formation and whether the content of that subconjunctival bleb was composed of refluxed bevacizumab.
The results obtained in group 1 and group 2 were compared. Statistical analysis was performed using unpaired t test and commercially available software (STATA 8; StataCorp LP, College Station, Texas).
Twelve eyes of 12 New Zealand white rabbits were included in the study. After randomization, 6 eyes were included in each group (group 1 and group 2). In group 2 eyes, the IOP was lowered by anterior chamber paracentesis using the aforedescribed technique. All study eyes were injected with the bevacizumab–trypan blue mixture. After the second randomization, 2 eyes in each group were injected using 27-, 30-, or 32-gauge needles.
Eyes in group 1 had a median IOP of 17.5 mm Hg (range, 17-18 mm Hg). Eyes injected using 27-gauge needles showed trypan blue–stained subconjunctival blebs with a median size of 3 mm (range, 2.9-3.1 mm) (Figure, A). Eyes injected using 30-gauge needles showed trypan blue–stained subconjunctival blebs with a median size of 1.7 mm (range, 1.6-1.8 mm). Eyes injected using 32-gauge needles showed no subconjunctival bleb formation.
Trypan blue–stained subconjunctival blebs secondary to reflux after intravitreous bevacizumab injection. A, Group 1 eye with a 3.1-mm subconjunctival bleb after intravitreous injection using a 27-gauge needle. B, Group 2 eye with a 0.7-mm subconjunctival bleb after intravitreous injection using a 27-gauge needle.
To lower the IOP, eyes in group 2 underwent anterior chamber paracentesis before intravitreous injection. After this procedure, eyes in group 2 had a median IOP of 10.3 mm Hg (range, 10-11 mm Hg). Eyes injected using 27-gauge needles showed trypan blue–stained subconjunctival blebs with a median size of 0.7 mm. Eyes injected using 30- or 32-gauge needles showed no subconjunctival bleb formation (Figure, B).
Comparing the effects of 32-gauge vs 30-gauge and 27-gauge needles in group 1, the median size of subconjunctival blebs differed significantly (P = .003 and P = .001, respectively). Comparing the effects of 27-gauge vs 30-gauge needles in group 1, the median size of subconjunctival blebs also differed significantly (P = .01).
The effects of 32-gauge and 30-gauge vs 27-gauge needles were compared in group 2. The median size of subconjunctival blebs differed significantly (P < .001).
Comparing the effects of 27-gauge needles in group 1 vs group 2, the median size of subconjunctival blebs differed significantly (P = .002). Comparing the effects of 30-gauge needles in group 1 vs group 2, the median size of subconjunctival blebs also differed significantly (P = .003).
In 1911, Ohm36 introduced the use of intravitreous injections of air to repair retinal detachment. In the 1940s, penicillin was used to treat endophthalmitis.37 Today, intravitreous drug injections provide an effective route for retinal disease therapy. Since the advent of anti-VEGF therapies, use of the intravitreous injection technique has steadily increased. However, concern has been expressed about potential unwanted secondary systemic absorption of these drugs.16,17 The effects may lead to serious complications such as systemic hypertension, thromboembolic diseases, and death.38,39
A 2007 study40 evaluated short-term IOP after intravitreous bevacizumab injection. The authors reported IOP elevation 30 minutes after intravitreous injection in a few patients. These results have been confirmed by others in 2 studies.41,42 In one study,41 some patients required eyedrops to lower the IOP; however, no patients needed anterior chamber paracentesis. In the other study,42 IOP of less than 30 mm Hg was seen 15 minutes after intravitreous injection in all patients, also without need for anterior chamber paracentesis. Nevertheless, a point of concern is that reflux may occur after intravitreous bevacizumab injection following removal of the needle, causing a subconjunctival bleb that may contain some of the injected drug,26 which might affect drug bioavailability and absorption. To minimize the amount of vitreous reflux, a modified technique using a tunneled scleral incision has been suggested.28 Anterior chamber paracentesis before intravitreous injection may prevent reflux, ensuring that the complete dose of the agent used remains in the vitreous cavity; however, anterior chamber paracentesis per se carries the risks of infection and lens damage.32
While injecting intravitreous bevacizumab in our practice, we observed that the drug inside the eye has an oily appearance. It adheres to the tip of the needle and is “pulled” to the vitreous base when withdrawing the needle (video; http://www.archophthalmol.com).
Herein, we considered not only the effects of needle diameter and an oblique injection technique as suggested by previous authors27,28 but also the possible key role of IOP in reflux after intravitreous injection. Our results showed that decreasing the IOP before intravitreous injection and using a smaller-gauge needle reduce the amount of drug reflux after intravitreous bevacizumab injection.
In conclusion, we observed in our cohort of eyes that subconjunctival blebs formed after intravitreous injection contain bevacizumab instead of fluid vitreous humor alone. In addition, the size of subconjunctival blebs is in direct proportion to the IOP and the needle diameter. Limitations of our study include our small sample size, as well as reported IOP measurement variation in New Zealand white rabbits.43 Until larger prospective randomized interventional studies are performed, we recommend decreasing the IOP before intravitreous bevacizumab injection and using a 32-gauge needle and an oblique injection technique. This technique includes placement of a cotton swab at the injection point immediately after removal of the needle in an effort to avoid reflux of bevacizumab, which may enter the systemic circulation. Intraocular pressure can be reduced by anterior chamber paracentesis.32 However, in our practice we prefer to place a mercury bag over the eye for 20 to 30 minutes before intravitreous injection. This is effective and avoids the risks associated with anterior chamber paracentesis.
Correspondence: G. Paolo Giuliari, MD, Princess Margaret Hospital, University of Toronto, 77 Elm St, Apt 903, Toronto, ON M5G 1H4, Canada (firstname.lastname@example.org).
Submitted for Publication: October 12, 2009; final revision received December 20, 2009; accepted January 7, 2010.
Financial Disclosure: None reported.
Additional Contributions: The Animal Research Department of the Universidad Central de Venezuela assisted with this study.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
Intravitreous Bevacizumab Injection: An Experimental Study in New Zealand White Rabbits
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.